Dr Moore talks to ecancertv at ASCO 2014 about the findings from a federally funded phase III clinical trial, S0230/POEMS, which indicate that adding a hormone suppressing drug called goserelin to standard chemotherapy may be an effective method of preserving fertility among women with early-stage hormone receptor-negative breast cancer.

ecancer's filming at ASCO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.